Skye Bioscience (SKYE) Fundamental Analysis: Revenue, Earnings & Valuation

8.76 / 10

Outperform

Fundamental rating is Outperform. Interest coverage, PB‑ROE, Revenue‑MV and Asset‑MV score high, indicating solid profitability and valuation. Inventory turnover and revenue growth are robust. However, current liabilities dominate total liabilities (~99%), raising a caution flag despite overall excellent quality.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score3/3

Weight30.89%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.42%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.52%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value98.99

Score0/3

Weight-13.05%

1M Return-4.96%

PB-ROE

Value-0.25

Score3/3

Weight38.91%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.00

Score2/3

Weight-1.09%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.58%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.38%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight54.24%

1M Return11.61%

Is SKYE undervalued or overvalued?

SKYE scores 8.76/10 on fundamentals and holds a Discounted valuation at present. Backed by its -126.85% ROE, 0.00% net margin, -0.42 P/E ratio, 1.16 P/B ratio, and -93.15% earnings growth, these metrics solidify its Outperform investment rating.